相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas
Cesar Serrano et al.
CANCER (2016)
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
Z. Eroglu et al.
BRITISH JOURNAL OF CANCER (2015)
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Jack F. Shern et al.
CANCER DISCOVERY (2014)
Prognostic Impact of the Activation Status of the Akt/mTOR Pathway in Synovial Sarcoma
Nokitaka Setsu et al.
CANCER (2013)
Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma
Xiang Chen et al.
CANCER CELL (2013)
Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Makoto Endo et al.
CLINICAL CANCER RESEARCH (2013)
NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition
Rebecca D. Dodd et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas
Nokitaka Setsu et al.
CANCER (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Phase 2 Study of Temsirolimus (CCI-779) in Patients With Soft Tissue Sarcomas A Study of the Mayo Phase 2 Consortium (P2C)
Scott Okuno et al.
CANCER (2011)
Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).
S. P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics
Laure Gibault et al.
JOURNAL OF PATHOLOGY (2011)
Cancer Therapy Based on Oncogene Addiction
Frank McCormick
JOURNAL OF SURGICAL ONCOLOGY (2011)
Resistance to MEK Inhibitors: Should We Co-Target Upstream?
Poulikos I. Poulikakos et al.
SCIENCE SIGNALING (2011)
Constant p53 Pathway Inactivation in a Large Series of Soft Tissue Sarcomas with Complex Genetics
Gaelle Perot et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Jordi Barretina et al.
NATURE GENETICS (2010)
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
Frederic Chibon et al.
NATURE MEDICINE (2010)
Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas
Joan Maurel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma
Jeffrey K. Mito et al.
PLOS ONE (2009)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ras oncogenes: split personalities
Antoine E. Karnoub et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
A spatially and temporally restricted mouse model of soft tissue sarcoma
David G. Kirsch et al.
NATURE MEDICINE (2007)
Phase III trial of two Investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study
Paul Lorigan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas
Eva Hernando et al.
NATURE MEDICINE (2007)
分享论文
